2023-507589-22-00
CTIS ↗
TYR300-101
Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations
pharma · Non-muscle invasive bladder cancer (NMIBC) · Low Grade Upper Tract Urothelial Carcinoma · TYRA
Tyra Biosciences
Tyra Biosciences trial registry — 9 ClinicalTrials.gov studies with program phase, status, and indication context.
Carlsbad, USA HQ
93 Employees
Public company Type
TYRA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Carlsbad, USA
- Employees
- 93
- Programs
- 9
- Drugs
- 3
- Patents
- 17
Tyra Biosciences clinical trials
Registry index of 9 ClinicalTrials.gov studies linked to Tyra Biosciences programs — each row shows trial ID, program name, phase, status, and indication.
Tyra Biosciences trial registry — 9 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Tyra Biosciences.
-
TYR200-101 — Phase 1
Clinical update -
TYR300-101 — Phase 2
Clinical update -
TYR300-202 — Phase 2
Clinical update -
Dabogratinib (TYRA-300) 60mg — Phase 2
Clinical update -
TYRA-300 — Phase 2
Clinical update -
TYRA-300 0.125 mg/kg — Phase 2
Clinical update -
TYRA-300 60mg — Phase 2
Clinical update -
TYRA-300-B01 — Phase 1
Clinical update